The overall ratings of five Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Targacept’s (NASDAQ:TRGT) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Targacept is an a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting neuronal nicotinic acetylcholine receptors. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, TRGT also gets F’s. For more information, get Portfolio Grader’s complete analysis of TRGT stock.
The rating of AVEO (NASDAQ:AVEO) slips from a D to an F. AVEO engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. The stock receives F’s in Earnings Revisions, Equity, and Cash Flow. Margin Growth and Sales Growth also get F’s. The stock price has fallen 13.9% over the past month, worse than the 2.5% increase the Nasdaq has seen over the same period of time. For a full analysis of AVEO stock, visit Portfolio Grader.
This week, Clovis Oncology Inc. (NASDAQ:CLVS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Clovis Oncology, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. It intends to target development programs for the treatment of specific subsets of cancer populations,… The stock gets F’s in Equity and Cash Flow. As of Feb. 20, 2013, 10.2% of outstanding Clovis Oncology Inc. shares were held short. To get an in-depth look at CLVS, get Portfolio Grader’s complete analysis of CLVS stock.
Slipping from C to a D rating, Cubist Pharmaceuticals (NASDAQ:CBST) takes a hit this week. Cubist Pharmaceuticals is involved in the research, development, and commercialization of pharmaceutical products in the acute-care market. The stock gets F’s in Earnings Momentum and Earnings Revisions. As of Feb. 20, 2013, 11.7% of outstanding Cubist Pharmaceuticals shares were held short. For more information, get Portfolio Grader’s complete analysis of CBST stock.
This week, Dendreon’s (NASDAQ:DNDN) rating worsens to an F from the company’s D rating a week ago. Dendreon is a biotechnology company that discovers, develops, and sells new therapeutics for cancer patients. The stock gets F’s in Earnings Momentum, Equity, and Cash Flow. As of Feb. 20, 2013, 32.3% of outstanding Dendreon shares were held short. To get an in-depth look at DNDN, get Portfolio Grader’s complete analysis of DNDN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.